文章基本信息

标题：Nanomedicine 2017 Anti-fusion targeted nanomicellar theranostics Novel antiviral strategies for respiratory syncytial virus infection-induced lung disease
本地全文：下载
作者：Shyam S Mohapatra
期刊名称：Journal of Research and Development
电子版ISSN：2311-3278
出版年度：2020
卷号：8
期号：2
页码：1-3
语种：English
出版社：OMICS International
摘要：The respiratory syncytial virus (RSV), is animportant pathogen that infects an estimated64 million people and causes ~200,000deaths globally every year. Despite progressin the biology of RSV, there is no effectivetreatment or vaccine against RSV infection.Currently, only high-risk infants receiveantibody-based prophylaxis, which isexpensive and moderately effective inreducing hospitalization. Therefore, abroadly applicable, effective andinexpensive approach to prevent or treatRSV-bronchiolitis or pneumonia remains anurgent unmet need. We have beeninvestigating nanomedical approachesagainst RSV infection and have reported ona variety of different strategies includinggenome vaccine, and siRNA-basednanoparticles. More recently, we havedeveloped a novel prophylaxis and/ortherapy against RSV infection was inspiredby the following discoveries: A platform ofphospholipid micellar nanoparticles (PMN)was developed, which when givenintranasally delivers payload predominantlyto the lung, A decoy short heptad repeat(HR)2 peptide was identified, whicheffectively inhibits the RSV-cell fusion. iii)Human mesenchymal cells were found to behighly susceptible to RSV.
关键词：polymorphisms ; Genetics;infants